Table 2.
Activity of m276-SL-PBD (single administration) in a single-mouse testing (SMT).
| Cancer Type | Model | Toxic Death |
Event | Time to Event |
AOC | minRTV | Objective Response Measure+ |
|---|---|---|---|---|---|---|---|
| CNS ATRT | BT-29 | 0 | 0 | > 112 | > 84.2 | 0.000 | CR |
| BT-35 | 0 | 1 | 65.0 | 52.8 | 0.000 | MCR | |
| BT-39 | 0 | 0 | > 147 | > 138.2 | 0.000 | MCR | |
| BT-40 | 0 | 0 | > 107 | > 104.7 | 0.000 | MCR | |
| BT-50 | 0 | 0 | > 147 | > 144.2 | 0.000 | MCR | |
| Ewing | CHLA-258‡ | 0 | 0 | > 119 | > 117.2 | 0.000 | MCR |
| ES-1‡ | 0 | 1 | 60.4 | 48.2 | 0.165 | PR | |
| ES-2‡ | 0 | 1 | 149.3 | 133.5 | 0.000 | CR | |
| ES-3‡ | 0 | 0 | > 133 | > 131.3 | 0.000 | MCR | |
| ES-4‡ | 0 | 0 | > 147 | > 146.1 | 0.000 | MCR | |
| ES-6‡ | 0 | 1 | 126.7 | 103.4 | 0.179 | PR | |
| ES-7‡ | 0 | 0 | > 107 | > 98.8 | 0.000 | MCR | |
| EW-5 | 0 | 1 | 18.1 | 6.2 | 2.862 | PD1 | |
| EW-8‡ | 0 | 0 | > 107 | > 90.0 | 0.000 | CR | |
| NCH-EWS-1 | 0 | 0 | > 70 | > 62.9 | 0.000 | MCR | |
| SK-NEP-1‡ | 0 | 1 | 106.2 | 81.7 | 0.000 | CR | |
| TC-71‡ | 0 | 0 | > 77 | > 54.5 | 0.114 | PR | |
| Rhabdoid | KT-12 | 0 | 0 | > 147 | > 145.2 | 0.000 | MCR |
| KT-14 | 0 | 0 | > 98 | > 95.7 | 0.000 | MCR | |
| KT-16 | 0 | 1 | 125.3 | 98.0 | 0.333 | PR | |
| NCH-RBD-1 | 0 | 0 | > 147 | > 144.9 | 0.000 | MCR | |
| NCH-RBD-2 | 0 | 0 | > 70 | > 69.0 | 0.000 | MCR | |
|
ERMS (Fusion-RMS) |
IRS-56 | 0 | 0 | > 119 | > 116.8 | 0.000 | MCR |
| JR-1‡ | 0 | 0 | > 107 | > 105.5 | 0.000 | MCR | |
| Rh-18 | 0 | 1 | 129.9 | 107.2 | 0.000 | CR | |
| Rh-36 | 0 | 0 | > 147 | > 145.6 | 0.000 | MCR | |
| SJR-HBO11-X | 0 | 1 | 24.7 | 13.0 | 1.299 | PD1 | |
| SJR-HBO13758-X2 | 0 | 1 | 15.8 | 6.6 | 1.942 | PD1 | |
| SMSCTR‡ | 0 | 1 | 63.2 | 45.9 | 0.177 | PR | |
| ARMS (Fusion+ RMS) | NCH-S13-7484 | 0 | 0 | > 126 | > 121.5 | 0.000 | MCR |
| Rh-28 | 0 | 0 | > 77 | > 75.7 | 0.000 | MCR | |
| Rh-30 | 0 | 0 | > 147 | > 144.0 | 0.000 | MCR | |
| Rh-30R | 0 | 0 | > 147 | > 145.1 | 0.000 | MCR | |
| Rh-65 | 0 | 0 | > 133 | > 131.4 | 0.000 | MCR | |
| Rh-66 | 0 | 0 | > 70 | > 66.4 | 0.000 | MCR | |
| Hepatoblastoma | CPRIT−1957 | 0 | 0 | > 70 | > 67.6 | 0.000 | MCR |
| Meningioma | NCH-S13-5042 | 0 | 1 | 24.5 | 12.6 | 1.272 | PD1 |
| Neuroblastoma | NB-1382‡ | 0 | 0 | > 107 | > 93.3 | 0.000 | MCR |
| NB-1643‡ | 0 | 0 | > 107 | > 104.0 | 0.000 | MCR | |
| Osteosarcoma | CPRIT-0522-000 | 0 | 0 | > 133 | > 122.7 | 0.000 | CR |
| OS-1 | 0 | 0 | > 107 | > 102.2 | 0.000 | MCR | |
| PXA* | S-12-6321 | 0 | 0 | > 147 | > 145.0 | 0.000 | MCR |
| Wilms | CPRIT-1960 | 0 | 0 | > 70 | > 66.7 | 0.000 | CR |
| KT-10 | 0 | 0 | > 147 | > 146.1 | 0.000 | MCR | |
| KT-11 | 0 | 0 | > 133 | > 132.1 | 0.000 | MCR | |
| KT-13 | 0 | 0 | > 147 | > 144.3 | 0.000 | MCR | |
| KT-5 | 0 | 0 | > 70 | > 68.0 | 0.000 | MCR |
Note: SMT experiments had N=1, thus p-values are not reported. m276-SL-PBD was given as a single administration at 0.5 mg/kg IP.
*
PXA, pleiomorphic xanthoastrocytoma.
‡
cell line-derived xenograft models.